Rosiglitazone

• CAT Number: A000942
• CAS Number: 122320-73-4
• Molecular Formula: C18H19N3O3S
• Molecular Weight: 357.40
• Purity: ≥95%
• Synonyms: 122320-73-4; Avandia; 5-(4-(2-(Methyl(pyridin-2-yl)amino)ethoxy)benzyl)thiazolidine-2,4-dione; Brl-49653; Rosiglizole
• Target: Vitamin D Related/Nuclear Receptor
• Solubility: >17.9mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
• InChI: InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)
• InChIKey: YASAKCUCGLMORW-UHFFFAOYSA-N
• SMILES: CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3

Rosiglitazone（Cat No.:A000942）is an antidiabetic medication belonging to the thiazolidinedione class, primarily used to improve insulin sensitivity in patients with type 2 diabetes mellitus. By activating peroxisome proliferator-activated receptor gamma (PPAR-γ), it regulates glucose and lipid metabolism, promoting adipocyte differentiation and reducing insulin resistance. Rosiglitazone has shown efficacy in lowering blood sugar levels and improving glycemic control. However, its use has been associated with concerns regarding cardiovascular risks, leading to regulatory scrutiny and a decline in its prescription. 

Reference

1: Cho RL, Lin WN, Wang CY, Yang CC, Hsiao LD, Lin CC, Yang CM. Heme oxygenase-1
induction by rosiglitazone via PKCα/AMPKα/p38 MAPKα/SIRT1/PPARγ pathway
suppresses lipopolysaccharide-mediated pulmonary inflammation. Biochem Pharmacol.
2018 Jan 5. pii: S0006-2952(17)30736-0. doi: 10.1016/j.bcp.2017.12.024. [Epub
ahead of print] PubMed PMID: 29309760.

2: Chistyakov DV, Azbukina NV, Lopachev AV, Kulichenkova KN, Astakhova AA,
Sergeeva MG. Rosiglitazone as a Modulator of TLR4 and TLR3 Signaling Pathways in
Rat Primary Neurons and Astrocytes. Int J Mol Sci. 2018 Jan 2;19(1). pii: E113.
doi: 10.3390/ijms19010113. PubMed PMID: 29301276.

3: Gong Y, Yin JY, Tong BD, Zeng JX, Xiong W. Low density lipoprotein –
rosiglitazone – chitosan-calcium alginate/nanoparticles inhibition of human
tenon/’s fibroblasts activation and proliferation. Oncotarget. 2017 Oct
9;8(62):105126-105136. doi: 10.18632/oncotarget.21757. eCollection 2017 Dec 1.
PubMed PMID: 29285239; PubMed Central PMCID: PMC5739626.

4: Wei R, Yu F, Yang J, Gao H, Wang H, Hong T. Anti-proliferative effect of
rosiglitazone in the human T-lymphocyte leukaemia cell line Jurkat cells. Cell
Biol Int. 2017 Dec 23. doi: 10.1002/cbin.10925. [Epub ahead of print] PubMed
PMID: 29274299.

5: Song A, Wu G, Hang H, Wang L. Rosiglitazone pretreatment influences
thrombin-induced anti-oxidative action via activating NQO1and γ-GCS in rat
microglial cells. Neurol Res. 2018 Feb;40(2):139-145. doi:
10.1080/01616412.2017.1417686. PubMed PMID: 29262765.

6: Wei L, Mao J, Lu J, Gao J, Zhu D, Tian L, Chen Z, Jia L, Wang L, Fu R.
Rosiglitazone Inhibits Angiotensin II-Induced Proliferation of Glomerular
Mesangial Cells via the Gαq/Plcβ4/TRPC Signaling Pathway. Cell Physiol Biochem.
2017 Dec 14;44(6):2228-2242. doi: 10.1159/000486056. [Epub ahead of print] PubMed
PMID: 29258063.

7: Xu J, Pan M, Wang X, Xu L, Li L, Xu C. Fluid Retention Caused by Rosiglitazone
Is Related to Increases in AQP2 and αENaC Membrane Expression. PPAR Res.
2017;2017:8130968. doi: 10.1155/2017/8130968. Epub 2017 Nov 2. PubMed PMID:
29230238; PubMed Central PMCID: PMC5688369.

8: Pankevich EV, Astakhova AA, Chistyakov DV, Sergeeva MG. Antiinflammatory
Effect of Rosiglitazone via Modulation of mRNA Stability of Interleukin 10 and
Cyclooxygenase 2 in Astrocytes. Biochemistry (Mosc). 2017 Nov;82(11):1276-1284.
doi: 10.1134/S0006297917110050. PubMed PMID: 29223154.

9: Wu G, Jiao Y, Wu J, Ren R, Wang L, Tang Z, Zhou H. Rosiglitazone infusion
therapy following minimally invasive surgery for ICH evacuation decreased
perihematomal glutamate content as well as BBB permeability in rabbits. World
Neurosurg. 2017 Dec 1. pii: S1878-8750(17)32077-6. doi:
10.1016/j.wneu.2017.11.145. [Epub ahead of print] PubMed PMID: 29203310.

10: Rondón-Ortiz AN, Lino Cardenas CL, Martínez-Málaga J, Gonzales-Urday AL,
Gugnani KS, Böhlke M, Maher TJ, Pino-Figueroa AJ. High Concentrations of
Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells. Front
Pharmacol. 2017 Nov 14;8:772. doi: 10.3389/fphar.2017.00772. eCollection 2017.
PubMed PMID: 29201005; PubMed Central PMCID: PMC5696635.